Non-nucleoside reverse transcriptase inhibitors

Mechanism of action and key advantages

The group of non-nucleoside reverse transcriptase inhibitors was developed as a safer and more effective alternative to nucleoside analogues. The main target of these drugs is the reverse transcriptase enzyme of human immunodeficiency virus type 1 (HIV-1).

The drugs bind directly to the enzyme, positioning themselves in close proximity to its catalytic center. This leads to an alteration in the three-dimensional structure (conformation) of reverse transcriptase. As a result, enzyme activity drops sharply, viral RNA transcription is suppressed, and the synthesis of proviral DNA—without which viral replication is impossible—is blocked. This type of inhibition is non-competitive in nature.

Compared to their predecessors (nucleoside inhibitors), the new group has a number of significant advantages:

• No need for activation: the drugs do not need to undergo phosphorylation within the cell.
• Different blocking mechanism: they do not incorporate into the growing viral DNA chain during synthesis.
• High selectivity: the drugs do not suppress human cellular DNA polymerase, significantly reducing their toxicity (specifically, they do not cause severe hematopoietic disorders).
• Overcoming resistance: they retain efficacy against viral strains that have already developed resistance to nucleoside analogues.

Spectrum of activity and resistance

The clinical utility of the group is strictly limited: the drugs are active only against HIV-1. They are ineffective against human immunodeficiency virus type 2 (HIV-2) and other known retroviruses. The main representatives of the class include efavirenz, nevirapine, and delavirdine.

The main problem with these medications is the rapid development of viral resistance. Moreover, the group is characterized by cross-resistance: if HIV mutates and becomes resistant to one of the drugs, the remaining drugs in this class also lose their efficacy. The only exception to date is etravirine—a newer drug capable of suppressing HIV-1 strains resistant to other NNRTIs.

Due to the high risk of resistance development, monotherapy with these agents is strictly unacceptable. In clinical practice, they are prescribed exclusively as part of combination therapy, supplementing the regimen with nucleoside reverse transcriptase inhibitors and protease inhibitors.

Pharmacokinetics and metabolism

All representatives of the group undergo active hepatic metabolism. Cytochrome P450 isoenzymes, primarily CYP3A4, play a key role in their biotransformation.

Because these drugs can affect the activity of metabolic enzymes, their administration carries a high risk of clinically significant drug-drug interactions. In some cases, the phenomenon of autoinduction is observed, where the drug stimulates the production of enzymes that accelerate its own degradation in the body.

Characteristics of main representatives

Each drug in the group has its own pharmacokinetic features and specific adverse reaction profile. A common side effect for the entire class is the risk of allergic reactions manifesting as a skin rash.

Efavirenz It is characterized by good gastrointestinal absorption (bioavailability of about 50%) and a long half-life (40 to 55 hours). This allows patients to take the tablets just once daily.

Specific side effects of efavirenz:

• Central nervous system: patients frequently complain of dizziness, insomnia, dysphoria, and decreased concentration.
• Psychotic disorders: particularly at the start of therapy, depressive states, mania, delusions, and hallucinations may occur.
• Teratogenicity: the drug is strictly contraindicated during pregnancy due to the risk of fetal abnormalities.

Nevirapine It has a very high bioavailability, reaching up to 90%. It is characterized by a pronounced autoinduction phenomenon: while the half-life is about 45 hours during the first days of treatment, it subsequently drops to 25–30 hours due to accelerated metabolism.

Specific side effects of nevirapine:

• Hepatotoxicity: the drug can cause severe liver damage, including elevated liver transaminases and severe hepatitis, which can be fatal.

Briefly: answers to topical questions

Class and exam questions

What else to study on this topic

• Detailed mechanism of non-competitive enzyme inhibition.
• The role of the CYP3A4 isoenzyme in drug-drug interactions.
• Principles of designing combination antiretroviral therapy.
• Teratogenic effects of medicinal products using efavirenz as an example.
• The phenomenon of hepatic enzyme autoinduction.

Other topics in the "Antivirals" section

Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.